Navigation Links
Prostate cancer biomarkers identified in seminal fluid
Date:6/6/2014

Improved diagnosis and management of one of the most common cancers in men prostate cancer could result from research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease.

Results of a study now published in the journal Endocrine-Related Cancer have shown that the presence of certain molecules in seminal fluid indicates not only whether a man has prostate cancer, but also the severity of the cancer.

Speaking in the lead-up to Men's Health Week (9-15 June), University of Adelaide research fellow and lead author Dr Luke Selth says the commonly used PSA (prostate specific antigen) test is by itself not ideal to test for the cancer.

"While the PSA test is very sensitive, it is not highly specific for prostate cancer," Dr Selth says. "This results in many unnecessary biopsies of non-malignant disease. More problematically, PSA testing has resulted in substantial over-diagnosis and over-treatment of slow growing, non-lethal prostate cancers that could have been safely left alone.

"Biomarkers that can accurately detect prostate cancer at an early stage and identify aggressive tumors are urgently needed to improve patient care. Identification of such biomarkers is a major focus of our research," he says.

Dr Selth, a Young Investigator of the Prostate Cancer Foundation (USA), is a member of the Freemasons Foundation Centre for Men's Health at the University of Adelaide and is based in the University's Dame Roma Mitchell Cancer Research Laboratories.

Using samples from 60 men, Dr Selth and colleagues discovered a number of small ribonucleic acid (RNA) molecules called microRNAs in seminal fluid that are known to be increased in prostate tumors. The study showed that some of these microRNAs were surprisingly accurate in detecting cancer.

"The presence of these microRNAs enabled us to more accurately discriminate between patients who had cancer and those who didn't, compared with a standard PSA test," Dr Selth says. "We also found that the one specific microRNA, miR-200b, could distinguish between men with low grade and higher grade tumors. This is important because, as a potential prognostic tool, it will help to indicate the urgency and type of treatment required."

This research builds on previous work by Dr Selth's team, published in the British Journal of Cancer, which demonstrated that microRNAs in the blood can predict men who are likely to relapse after surgical removal of their prostate cancer. "We are excited by the potential clinical application of microRNAs in a range of body fluids," he says.


'/>"/>

Contact: Dr. Luke Selth
luke.selth@adelaide.edu.au
61-882-223-618
University of Adelaide
Source:Eurekalert

Related biology news :

1. Circumcision linked to reduced risk of prostate cancer in some men
2. Prostate cancer and blood lipids share genetic links
3. Circumcision could prevent prostate cancer... if its performed after the age of 35
4. A gene family that suppresses prostate cancer
5. CNIO researcher awarded by the Prostate Cancer Foundation
6. Cholesterol study suggests new diagnostic, treatment approach for prostate cancer
7. Targeting metabolism to develop new prostate cancer treatments
8. Myriads Prolaris significantly modifies treatment decisions for prostate cancer patients
9. Mechanism affecting risk of prostate cancer is found
10. Genetic mutation may play key role in risk of lethal prostate cancer in overweight patients
11. Men with prostate cancer who ate a low-fat fish oil diet showed changes in their cancer tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... Administration (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain ... for adults at home or in healthcare facilities during periods of rest. A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, ... cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using ... Salimetrics’ SalivaLab , the relationship between insulin and other relevant biomarkers can ...
(Date:2/23/2017)... 23, 2017 Aviva Systems Biology Corporation ... acquisition of GenWay Biotech Incorporated, a protein solutions ... product offering for both the research and diagnostic ... and enhance capabilities for both entities. GenWay,s 18 years ... will nicely complement ASB,s objective to become a ...
Breaking Biology Technology: